Starboard to vote against Bristol-Myers’ $74 billion deal for Celgene


Activist investor Starboard Value LP will vote against Bristol-Myers Squibb Co’s $74 billion acquisition of Celgene Corp, the hedge fund said on Thursday, the latest shareholder to come out against what would be the pharmaceutical world’s biggest ever takeover.